<?xml version="1.0" encoding="iso-8859-1" ?>
<newsitem itemid="726304" id="root" date="1997-07-14" xml:lang="en">
<title>USA: Vertex stock falls after analyst report.</title>
<headline>Vertex stock falls after analyst report.</headline>
<dateline>NEW YORK 1997-07-14</dateline>
<text>
<p>Shares of Vertex Pharmaceuticals Inc fell sharply Monday after an analyst said progress had slowed in clinical trials of its protease inhibitor to treat HIV infection and AIDS.</p>
<p>A Hambrecht &amp; Quist report also urged investors to be cautious about the protease inhibitor market during the next several months because of accounts of emerging drug resistance in HIV patients using existing triple-combination therapies.</p>
<p>Vertex' stock fell 4-3/4 to 33-1/8, with analysts attributing the decline to the Hambrecht &amp; Quist report, released earlier in the day.  </p>
<p>Glaxo Wellcome Plc has licensed the Vertex compound, 141W94, and is using it in separate adult and pediatric Phase III trials in combination with Glaxo reverse transcriptase inhibitors AZT and 3TC.</p>
<p>Hambrecht &amp; Quist said 141W94 would probably not be available until the end of 1998, adding Glaxo had commented earlier that development had been slowed down because of a manufacturing problem with a batch of the drug.</p>
<p>Glaxo spokesman Ramona Jones said she had not seen the Hambrecht &amp; Quist report, but added said she was not aware of any recent manufacturing delays.</p>
<p>&quot;We're on schedule for 141W94 and expect to file a new drug application in 1998&quot; with the U.S. Food and Drug Administration, she said.</p>
<p>Jones said she was unable to predict when the drug might reach the market, if approved by the FDA.</p>
<p>(( Ransdell Pierson, New York Newsdesk, 212 859-1700))</p>
</text>
<copyright>(c) Reuters Limited 1997</copyright>
<metadata>
<codes class="bip:countries:1.0">
  <code code="USA">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-07-14"/>
  </code>
</codes>
<codes class="bip:industries:1.0">
  <code code="I25700">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-07-14"/>
  </code>
</codes>
<codes class="bip:topics:1.0">
  <code code="C15">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-07-14"/>
  </code>
  <code code="C152">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-07-14"/>
  </code>
  <code code="C23">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-07-14"/>
  </code>
  <code code="CCAT">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-07-14"/>
  </code>
</codes>
<dc element="dc.date.created" value="1997-07-14"/>
<dc element="dc.publisher" value="Reuters Holdings Plc"/>
<dc element="dc.date.published" value="1997-07-14"/>
<dc element="dc.source" value="Reuters"/>
<dc element="dc.creator.location" value="NEW YORK"/>
<dc element="dc.creator.location.country.name" value="USA"/>
<dc element="dc.source" value="Reuters"/>
</metadata>
</newsitem>
